

Haematologica
HAEMATOL/2017/176073
Version 3

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation

Jennifer Mosebach, Sofia Shah, Stefan Delorme, Thomas Hielscher, Hartmut Goldschmidt, Heinz-Peter Schlemmer, Stefan O. Schönland, Ute Hegenbart, and Jens Hillengass

Disclosures: The first author (J.Mosebach) receives Research/Grant Support from the German Research Foundation (Deutsche Forschungsgemeinschaft). Outside the submitted work the following relationships are reported: S.D.: Honoraria from Bracco and Forschungszentrum Ultraschall GmbH. H.G. reports Research Support: Celgene, Janssen, Chugai, Novartis, BMS; Advisory Boards: Janssen, Celgene, Novartis, Amgen Takeda, BMS; Honoraria: Celgene, Janssen, Novartis, Chugai, BMS. S.O.S.: Travel grant: Janssen, Medac, Binding Site; consultancy: Prothena, Janssen; research funding: Janssen, Celgene. U.H.: Travel grant: Janssen, Pfizer; consultancy: Prothena, Pfizer. J.H.: Consultancy: Amgen, Celgene; Honoraria: Janssen, Celgene, Novartis, Amgen, BMS, Takeda; Research Funding: Celgene, Sanofi; Advisory Board: Amgen, Novartis, Celgene, Janssen. S.S., T.H., and H-P.S. have nothing to disclose.

Contributions: J.H., J.M., S.S., and S.D. generated the study concept. J.M., S.D., and S.S. performed the image analysis. S.S., S.O.S., U.H., H.G. provided/collected clinical information and obtained follow-up information on events and survival. T.H. performed the statistical analysis. J.M., J.H., S.O.S., U.H., and H-P.S. carried out the interpretation of data. J.M., S.D. and J.H. wrote the manuscript. All authors approved the final version of the of the manuscript.